Corporate Overview

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.

Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Read more

Why Invest

3

ACTIVE DRUG PROGRAMS TARGETING MAJOR DEPRESSIVE DISORDER, ALCOHOL USE DISORDER, ANXIETY DISORDERS, AND NEUROINFLAMMATION

$130M

RAISED TO DATE TO PROGRESS M&A STRATEGY AND CLINICAL TRIALS

>50

GRANTED OR PENDING PATENT APPLICATIONS FILED ACROSS 6 PATENT FAMILIES

$22.5M

IN CASH AND EQUIVALENTS AS OF December 31, 2022

-->

$ in CAD

Latest News

View all news

Latest Presentation

Events and Conferences

View All Events

Latest Financial Reports

View All Financial Reports